Recombinant Human Tumor Necrosis Factor Receptor Type â…¡-IgG Fc Fusion Protein For Treatment Of Erythrodermic Psoriasis

Objective:To investigate the efficacy and safety of the recombinant human tumor necrosis factor receptor Ⅱ-IgG Fc fusion protein( rhTNFR:Fc, etanercept) for the treatment of erythrodermic psoriasis.Methods: 23 patients with erythrodermic psoriasis were treated with etanercept(25 mg,subcutaneous injection, twice per week, doubling of first dose). The course of treatment was 12 weeks, following up for two years. The Psoriasis Area and Severity Index(PASI)score, the proportion of patients achieving a 50%, 75% and 90% reduction in PASI(PASI50, PASI75, PASI90) and the serum level of TNF- α were used to assess the efficacy at different times. Adverse reactions were also recorded and evaluated. The results were statistically analyzed by nonparametric Friedman test and repetitive measurement ANOVA using the software SPSS19.0.Results: After 12 weeks treatment, the PASI score decreased form 57.35±3.45 to 5.57±3.60( P < 0.01). The PASI50, PASI75 and PASI90 were increased to 23(100%), 22(95.65%), and 14(60.87%), respectively. The serum level of TNF- α decreased form(62.87±15.23) pg/ml to(4.57±2.99) pg/ml( P<0.01). Statistically significant difference was observed from the above indexes. There were no adverse reactions in clinical application. Conclusion:Recombinant human tumor necrosis factor receptor Ⅱ-IgG Fc fusion protein is a safe and effective drug in the treatment of the acute phase of erythrodermic psoriasis.